FATE THERAPEUTICS INC Operating Lease, Expense
FATE THERAPEUTICS INC (FATE) reported Operating Lease, Expense of $3.50 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2020-05-11
- FATE THERAPEUTICS INC operating lease, expense for the quarter ending 2020-03-31 was $3.50M, a 133.33% increase year-over-year.
- FATE THERAPEUTICS INC operating lease, expense for the quarter ending 2019-12-31 was $1.50M.
- FATE THERAPEUTICS INC operating lease, expense for the quarter ending 2019-09-30 was $1.50M.
- FATE THERAPEUTICS INC operating lease, expense for the quarter ending 2019-06-30 was $1.50M.
- FATE THERAPEUTICS INC operating lease, expense for fiscal 2019 was $6.10M.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2020-03-31 | $3.50M 10-Q · filed 2020-05-11 | $5.00M derived: sum of 2 quarters · filed 2020-05-11 | $6.50M derived: sum of 3 quarters · filed 2020-05-11 | $8.00M derived: sum of 4 quarters · filed 2020-05-11 |
| 2019-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $3.00M derived: sum of 2 quarters · filed 2020-03-02 | $4.50M derived: sum of 3 quarters · filed 2020-03-02 | $6.10M 10-K · filed 2020-03-02 |
| 2019-09-30 | $1.50M 10-Q · filed 2019-11-05 | $3.00M derived: sum of 2 quarters · filed 2019-11-05 | $4.60M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $1.50M 10-Q · filed 2019-08-06 | $3.00M 10-Q · filed 2019-08-06 | ||
| 2019-03-31 | $1.50M 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |